Rosiglitazone on Microalbuminuria in Type 2 Diabetics
Status:
Completed
Trial end date:
2004-06-01
Target enrollment:
Participant gender:
Summary
Following a 4-week single-blind placebo run-in period, eligible subjects were randomized in a
1:1 ratio to receive 32 weeks of double-blind study medication: Rosiglitazone (starting dose
4mg od) or Glyburide (starting dose 5mg od), both in combination with open-label Metformin >
or = (1g/day). Subjects were stratified for use of ACEI, nondihydropyridine calcium channel
blockers (NDP CCB), or angiotensin II receptor blockers (ARB) to provide equal representation
of these subjects in each treatment group.